QR code

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer. However, in neuroblastoma, activating mutations in the ALK kinase domain are typically refractory to crizotinib treatment, highli...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: J. Guan, E. R. Tucker, H. Wan, D. Chand, L. S. Danielson, K. Ruuth, A. El Wakil, B. Witek, Y. Jamin, G. Umapathy, S. P. Robinson, T. W. Johnson, T. Smeal, T. Martinsson, L. Chesler, R. H. Palmer, B. Hallberg
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: The Company of Biologists 2016-09-01
Reeks:Disease Models & Mechanisms
Onderwerpen:
PF-06463922
Neuroblastoma
ALK
MYCN
Mouse models
Lorlatinib
Online toegang:http://dmm.biologists.org/content/9/9/941
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items